Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza

PHASE3TerminatedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions
Respiratory Viral Infection
Interventions
DRUG

ZX-7101A

On day1: Take two tablets of ZX-7101A orally once (specification: 10mg/ tablet) with appropriate amount of warm water

OTHER

Placebo for ZX-7101A tablet

"Placebo for ZX-7101A tablet:~The appearance and properties of placebo tablets were identical to those of the trial drug ZX-7101A tablets. On Day 1, two placebo for ZX-7101A tablets were taken orally with appropriate warm water."

DRUG

Oseltamivir phosphate dry suspension

"Drug: Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."

OTHER

Placebo for Oseltamivir phosphate dry suspension:

"Drug: Placebo for Oseltamivir phosphate dry suspension:~From Day1 to Day 5 : Placebo for Oseltamivir phosphate suspension was orally administered twice a day, dose according to the label."

Trial Locations (3)

Unknown

Baoding Hospital of Beijing Children's Hospital, Capital Medical University, Baoding

West China Second University Hospital, Sichuan University, Chengdu

Children's Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Nanjing Zenshine Pharmaceuticals

INDUSTRY

NCT06669351 - Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza | Biotech Hunter | Biotech Hunter